Department for Hematology and Medical Oncology, Justus-Liebig University Hospital, Giessen, Germany.
J Natl Compr Canc Netw. 2010 Sep;8 Suppl 6:S1-14; quiz S15. doi: 10.6004/jnccn.2010.0129.
Non-Hodgkin's lymphoma (NHL) represents a diverse group of hematologic malignancies originating in B or T lymphocytes. Approximately 85% of NHLs are of B-cell origin, with the remainder mostly of T-cell origin. The most common NHL types are diffuse large B-cell lymphoma (31%) and follicular lymphoma (22%). More than 65,000 new cases of NHL develop each year, and approximately 20,000 people with NHL died of the disease 2009. NHL is the seventh most common cancer in the United States, contributes to approximately 4% to 5% of all cancer cases in the United States, and causes approximately 3% of all cancer-related deaths. Currently, nearly 500,000 people are living with the disease or are in remission. Several new and encouraging advances have been made in the treatment of indolent NHL. Although the watch and wait approach still has a role, combined immunochemotherapy remains the standard of care for both first-line and relapsed/refractory disease. As front-line treatment, bendamustine plus rituximab may become a new standard of care, especially for older patients. In contrast, rituximab in combination with chemotherapy followed by rituximab maintenance seems to be the optimal option in patients with relapsed disease.
非霍奇金淋巴瘤（NHL）是一组起源于 B 或 T 淋巴细胞的血液系统恶性肿瘤。大约 85%的 NHL 来源于 B 细胞，其余大多来源于 T 细胞。最常见的 NHL 类型是弥漫性大 B 细胞淋巴瘤（31%）和滤泡性淋巴瘤（22%）。每年新增 NHL 病例超过 65000 例，2009 年约有 20000 人死于 NHL。NHL 是美国第七大常见癌症，约占美国所有癌症病例的 4%至 5%，导致约 3%的癌症相关死亡。目前，近 50 万人患有该疾病或处于缓解期。在惰性 NHL 的治疗方面已经取得了一些新的令人鼓舞的进展。尽管观察和等待的方法仍然具有一定的作用，但联合免疫化疗仍然是一线和复发/难治性疾病的标准治疗方法。作为一线治疗，苯达莫司汀联合利妥昔单抗可能成为新的标准治疗方法，尤其是对老年患者而言。相比之下，利妥昔单抗联合化疗后进行利妥昔单抗维持治疗似乎是复发患者的最佳选择。
